Panacea Biotec up 13% on US FDA nod for migraine drug
US FDA gave a clearance to the company's drug which is used to treat symptoms due to migraine. | Shares of Panacea Biotec zoomed over 13 percent intraday on Wednesday as the company received the US drug regulator’s nod for a drug. The company got the US Food and Drug Administration’s (FDA) approval for Rizatripan Bonzoate tablet, which is used to treat symptoms due to migraine. The stock has seen a good upside, with an upward movement of over 16% in the last month. Late in December, the scrip had seen a 10% intraday jump on the back of a vaccine roll out which is used in primary immunisation and as a booster dose against diphtheria, tetanus, among others. Panacea Biotec was quoting at Rs 141.00, up Rs 15.30, or 12.17 percent, on the BSE. It touched an intraday high of Rs 143.60 and an intraday low of Rs 134.20.
Read more for HNI Stock Tips-http://www.aceinvestmentadvisory.com
US FDA gave a clearance to the company's drug which is used to treat symptoms due to migraine. | Shares of Panacea Biotec zoomed over 13 percent intraday on Wednesday as the company received the US drug regulator’s nod for a drug. The company got the US Food and Drug Administration’s (FDA) approval for Rizatripan Bonzoate tablet, which is used to treat symptoms due to migraine. The stock has seen a good upside, with an upward movement of over 16% in the last month. Late in December, the scrip had seen a 10% intraday jump on the back of a vaccine roll out which is used in primary immunisation and as a booster dose against diphtheria, tetanus, among others. Panacea Biotec was quoting at Rs 141.00, up Rs 15.30, or 12.17 percent, on the BSE. It touched an intraday high of Rs 143.60 and an intraday low of Rs 134.20.
Read more for HNI Stock Tips-http://www.aceinvestmentadvisory.com
No comments:
Post a Comment